SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
Accelerating Domestic Clinical Trials and Targeting the Blue Ocean of Asthma Drugs
HONG KONG, May 22, 2023 - (ACN Newswire) - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that an Investigational New Drug ("IND") application for SM17 (a humanised anti-IL-17RB monoclonal antibody for injection) for the treatment of Asthma has been filed with and accepted by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration of China ("NMPA") on 19 May. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.
SM17 is a humanized, IgG4-k monoclonal antibody targeting IL-17RB, which is a global first-in-class monoclonal antibody drug targeting IL17BR with the potential for treating asthma, atopic dermatitis, idiopathic pulmonary fibrosis and other immunological disorders. This IND application is mainly for the treatment of asthma, and upon approval of the present IND, the Company plans to initiate a Phase I clinical study in China to bridge between Chinese(Asian) and American(Caucasian/Black) populations, as well as to investigate the safety profile of SM17 in Chinese population.
As early as March 2022, SM17's IND Application for the treatment of asthma was approved by the U.S. Food and Drug Administration ("FDA"), and the first healthy subject had been successfully dosed in a Phase I clinical First-in-Human(FIH) clinical trial in June 2022. As of today, none of the subjects reported a serious adverse event. We are in full steam ahead to accelerate the progress of our clinical study. According to our current progress, we expect the Phase I clinical study can be completed by the end of this year, six months ahead of the original anticipated completion date.
SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of airway viral responses and allergic disease, such as asthma. Patients with severe, uncontrolled asthma are at a risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality/morbidity, diminished quality of life and increased health expenditures.
As one of the global pandemic, asthma has huge urgent and unmet medical needs, and the pharmaceutical market has a broad space. According to the Frost & Sullivan Report, the number of asthma patients worldwide is gradually increasing and expected to reach 800 million in 2024 and further increase to approximately 860 million in 2030. The number of asthma patients in China grew faster than the global growth rate and is expected to reach 70.4 million in 2024 and further increase to 78.1 million in 2030. In terms of market size, the global asthma product market is expected to reach US $38.5 billion in 2024 and US $50 billion by 2030. The asthma product market in China is expected to reach US $5.6 billion by 2024 and US $9.7 billion by 2030, of which the market size of moderate-to-severe asthma applicable for biologics will reach US $6.6 billion. Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent. However, there is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB, will have a broad effect on airway inflammation and improve disease conditions. The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.
Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that, "The number of asthma patients worldwide has increased year by year, and the existing therapies have not fully met the medical needs, and there is still a huge gap in effective treatment of severe asthma. As the world's first humanized IgG4-k monoclonal antibody targeting IL-17RB, SM17 has made satisfactory progress in clinical research under the active promotion of the Company. The acceptance of IND Application for SM17 not only accelerated the Company's clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. The Company is confident in the prospects of clinical trial and commercial development of the new drug of SM17, and will continue to explore its safety and efficacy. It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients. The Company will adhere to independent innovation, continue to promote the investigatory of new drugs, expand the population of indications, spare no effort to provide more effective treatment options for Chinese and global patients, aiming to become a global leader in innovative therapies for immunological diseases."
About SinoMab BioScience Limited SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.
This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact:
Financial PR (HK) Limited Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Cita Zhang / Ms. Willa Xue Email: sinomab@financialpr.hk Tel: (852) 2610 0846 Fax: (852) 2610 0842
Source: SinoMab BioScience Limited Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles May 15, 2024 14:30 JST
| Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status May 15, 2024 11:19 JST
| SMEIC Proposes to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern May 14, 2024 21:54 JST
| DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot May 14, 2024 11:02 JST
| Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings May 13, 2024 18:32 JST
| Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures May 13, 2024 17:06 JST
| Ogier and TOYOTA GAZOO Racing triumph again May 13, 2024 14:36 JST
| Spa points haul for TOYOTA GAZOO Racing May 13, 2024 13:56 JST
| DOCOMO to Launch NTT DOCOMO GLOBAL for Global Expansion May 10, 2024 18:13 JST
| Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku" May 10, 2024 12:20 JST
| Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024 May 09, 2024 20:39 JST
| Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore May 09, 2024 19:00 JST
| Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India May 09, 2024 14:13 JST
| Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning May 09, 2024 10:41 JST
| Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance May 08, 2024 14:27 JST
| Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers May 08, 2024 12:00 JST
| NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement May 08, 2024 10:24 JST
| ServiceNow and Fujitsu announce strategic commitment to launch innovative cross-industry solutions May 08, 2024 08:52 JST
| Fujitsu launches mainframe modernization automation service for the Japanese market May 07, 2024 17:53 JST
| MHI Agrees to Collaborate with Chiyoda Corporation for Licensing of CO2 Capture Technologies May 07, 2024 13:49 JST
|
More Latest Release >>
|